Cargando…

Recombinant factor IX‐Fc fusion protein in severe hemophilia B: Patient‐reported outcomes and health‐related quality of life

INTRODUCTION: In 2017, all people with severe hemophilia B in Ireland switched to recombinant factor IX Fc fusion protein concentrate (rFIXFc) prophylaxis. Patient‐reported outcomes (PROs) and health‐related quality of life (HRQoL) are important to evaluate with new treatments. AIMS: To assess HRQoL...

Descripción completa

Detalles Bibliográficos
Autores principales:	O’Donovan, Mairead, Quinn, Eimear, Johnston, Kate, Singleton, Evelyn, Benson, Julie, O'Mahony, Brian, Noone, Declan, Duggan, Cleona, Gilmore, Ruth, Ryan, Kevin, O'Donnell, James S., O’Connell, Niamh M., Mahlangu, Johnny
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505226/ https://www.ncbi.nlm.nih.gov/pubmed/34667923 http://dx.doi.org/10.1002/rth2.12602

Ejemplares similares

Issues in assessing products for the treatment of hemophilia – the intersection between efficacy, economics, and ethics
por: Farrugia, Albert, et al.
Publicado: (2015)

Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies
por: Chowdary, Pratima, et al.
Publicado: (2022)

Physical activity, physical fitness and cardiometabolic risk amongst adults with moderate and severe haemophilia
por: Kennedy, Megan, et al.
Publicado: (2022)

Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B
por: Shapiro, Amy D., et al.
Publicado: (2023)

Recombinant factor IX Fc for major surgery in hemophilia B: factor IX plasma activity levels and effective hemostasis
por: Shapiro, Amy D., et al.
Publicado: (2023)

Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH
por: Konkle, Barbara, et al.
Publicado: (2020)

Biodistribution of recombinant factor IX, extended half-life recombinant factor IX Fc fusion protein, and glycoPEGylated recombinant factor IX in hemophilia B mice
por: van der Flier, Arjan, et al.
Publicado: (2023)

Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors
por: Kempton, Christine, et al.
Publicado: (2021)

Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand
por: Álvarez-Román, María-Teresa, et al.
Publicado: (2023)

Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B
por: Mahlangu, Johnny N.
Publicado: (2018)

Extending recombinant factor IX Fc fusion protein dosing interval to 14 or more days in patients with hemophilia B
por: Shapiro, Amy D., et al.
Publicado: (2018)

Coagulation Factor IX for Hemophilia B Therapy 
por: Orlova, N. A., et al.
Publicado: (2012)

Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice
por: Toby, Garabet G., et al.
Publicado: (2016)

Reformulation of Processed Yogurt and Breakfast Cereals over Time: A Scoping Review
por: O’Mahony, Sinead, et al.
Publicado: (2023)

Knowledge and attitudes of Irish GPs towards abortion following its legalisation: a cross-sectional study
por: O'Connor, Raymond, et al.
Publicado: (2019)

Evolution of Haemophilia Care in Europe: 10 years of the principles of care
por: Noone, D., et al.
Publicado: (2020)

Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX‐Fc fusion protein: A randomized trial
por: Escuriola Ettingshausen, Carmen, et al.
Publicado: (2019)

Changing paradigms of hemophilia care across larger specialized treatment centers in the European region
por: Windyga, Jerzy, et al.
Publicado: (2022)

Treatment of hemophilia B: focus on recombinant factor IX
por: Franchini, Massimo, et al.
Publicado: (2013)

The Clinical Genetics of Hemophilia B (Factor IX Deficiency)
por: Miller, Connie H
Publicado: (2021)

Association of factor expression levels with annual bleeding rate in people with haemophilia B
por: Burke, Tom, et al.
Publicado: (2022)

Haemostatic Disarray Following COVID-19 Vaccine – a Case of Acquired Haemophila A
por: O'Shea, Evelyn, et al.
Publicado: (2022)

Antithrombin inhibition using nanobodies to correct bleeding in hemophilia
por: O'Sullivan, Jamie M, et al.
Publicado: (2020)

GlycoPEGylated recombinant factor IX for hemophilia B in context
por: Santagostino, Elena, et al.
Publicado: (2018)

Combined thrombin-collagen injection for the management of an iatrogenic pseudoanuerysm in the popliteal region
por: McCarthy, Eoghan, et al.
Publicado: (2012)

Interacting with patients at risk of self-harm or suicide - A qualitative study of community pharmacists and pharmacy staff
por: O'Driscoll, Michelle, et al.
Publicado: (2023)

A systematic review of physical activity in people with haemophilia and its relationship with bleeding phenotype and treatment regimen
por: Kennedy, Megan, et al.
Publicado: (2021)

Measuring social exclusion in healthcare settings: a scoping review
por: O’Donnell, Patrick, et al.
Publicado: (2018)

Omani experience with the use of factor IX Fc fusion protein
por: Alzadjali, Shireen I, et al.
Publicado: (2021)

Bifidobacterium Infantis 35624 Protects Against Salmonella-Induced Reductions in Digestive Enzyme Activity in Mice by Attenuation of the Host Inflammatory Response
por: Symonds, Erin L, et al.
Publicado: (2012)

“We’re not educated on that enough, and we really should be”: adolescents’ views of mental health service education
por: Goodwin, John, et al.
Publicado: (2023)

HCV Genotypes of People with Hemophilia in Countries with High Seroprevalances
por: Mahlangu, J N, et al.
Publicado: (2011)

Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults
por: Konkle, Barbara A., et al.
Publicado: (2023)

Discovery of an Orally Effective Factor IX-Transferrin Fusion Protein for Hemophilia B
por: Xie, Chen, et al.
Publicado: (2019)

Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments
por: Bowyer, Annette E., et al.
Publicado: (2022)

Unchallenged good intentions: a qualitative study of the experiences of medical students on international health electives to developing countries
por: O’Donnell, Patrick, et al.
Publicado: (2014)

Immune system in the intestine and mucosal inflammation
por: O'Mahony, Liam
Publicado: (2011)

The Brain-Based Classroom
por: O'Mahony, Kieran
Publicado: (2020)

Infection control in general practices in Buffalo City and OR Tambo District Municipalities, South Africa
por: O'Mahony, Don
Publicado: (2012)

EU Regulatory Risk Management of Marine Biotoxins in the Marine Bivalve Mollusc Food-Chain
por: O’Mahony, Micheál
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_h2ua4si91fq85ns05qn9738t68